Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 10/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30197770 | 1.00 | P2RX7 (0.48) | P2RX7L3MBTL1POLBMAPTTP53 | |
| SCHEMBL24875255 | 0.87 | P2RX7 (0.45) | P2RX7L3MBTL1MAPTKDM4EKMT2A | |
| SCHEMBL30192787 | 0.87 | P2RX7 (0.45) | P2RX7L3MBTL1MAPTKDM4EKMT2A | |
| SCHEMBL3801839 | 0.84 | HTT (0.46) | P2RX7L3MBTL1POLBMAPTALDH1A1 | |
| SCHEMBL29836179 | 0.83 | SMN1; SMN2 (0.48) | P2RX7ALDH1A1 | |
| SCHEMBL14186623 | 0.83 | GAA (0.46) | L3MBTL1POLBMAPTTP53ALDH1A1 | |
| SCHEMBL3967997 | 0.83 | SMN1; SMN2 (0.48) | P2RX7ALDH1A1 | |
| SCHEMBL837451 | 0.83 | ALDH1A1 (0.56) | P2RX7L3MBTL1POLBMAPTTP53 | |
| SCHEMBL1525623 | 0.81 | ALDH1A1 (0.54) | P2RX7L3MBTL1POLBMAPTTP53 | |
| SCHEMBL4711040 | 0.81 | ALDH1A1 (0.51) | P2RX7L3MBTL1ALDH1A1KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118702710-A | Method for synthesizing organoboron compound by visible light catalysis | 常州大学 | 2024-09-27 | — | — | CN | disclosed |
| CN-113149961-B | Azabicyclo-substituted triazole derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-11-22 | — | — | CN | disclosed |
| CN-107922437-B | Bridged piperidine derivatives | 豪夫迈·罗氏有限公司 | 2021-12-10 | — | — | CN | disclosed |
| US-20210040073-A1 | AZABICYCLO-SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREOF, AND APPLICATION OF SAME IN MEDICINE | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2021-02-11 | — | — | US | disclosed |
| US-10604517-B2 | Bridged piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-03-31 | — | — | US | disclosed |
| EP-3564231-A1 | AZABICYCLO-SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREOF, AND APPLICATION OF SAME IN MEDICINE | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2019-11-06 | — | — | EP | disclosed |
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-01-31 | — | — | US | disclosed |
| EP-3408256-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | Takeda Pharmaceutical Company Limited (JP) | 2018-12-05 | — | — | EP | disclosed |
| US-20180237432-A1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-08-23 | — | — | US | disclosed |
| EP-3347363-A1 | BRIDGED PIPERIDINE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2018-07-18 | — | — | EP | disclosed |
| WO-2010112437-A1 | 1-HETEROCYCLYL-1, 5-DIHYDRO-PYRAZOLO [3, 4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-07 | — | — | WO | disclosed |
| CN-101808992-A | 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives | HOFFMANN LA ROCHE | 2010-08-18 | — | — | CN | disclosed |
| EP-2205562-A1 | 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| EP-2181992-A1 | POLYCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2010-05-05 | — | — | EP | disclosed |
| WO-2009121919-A1 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-08 | — | — | WO | disclosed |
| US-20090088425-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | US | disclosed |
| WO-2009040288-A1 | 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | WO | disclosed |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2009-03-05 | — | — | US | disclosed |
| WO-2003076403-A1 | 1,2-DISUBSTITUDED-6-OXO-3-PHENYL-PIPERIDINE-3-CARBOXAMIDES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2003-09-18 | — | — | WO | disclosed |
| US-20030171588-A1 | 1,2-disubstituted-6-oxo-3-phenyl-piperidine-3-carboxamides and combinatorial libraries thereof | LION BIOSCIENCE AG (DE) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171588-A1 | 1,2-disubstituted-6-oxo-3-phenyl-piperidine-3-carboxamides and combinatorial libraries thereof | BRD4, BICRA, HDAC6 | P2RX7 269/4885L3MBTL1 3098/4885POLB 3105/4885 |
| US-20180237432-A1 | BRIDGED PIPERIDINE DERIVATIVES | HPGDS, APP, PSEN1 | P2RX7 1217/4885L3MBTL1 795/4885POLB 343/4885 |
| US-10604517-B2 | Bridged piperidine derivatives | HPGDS, APP, PSEN1 | P2RX7 1217/4885L3MBTL1 795/4885POLB 343/4885 |
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | GRM7, GRIN2B, GRM1 | P2RX7 86/4885L3MBTL1 2881/4885POLB 4221/4885 |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | APP, BACE1, PSEN1 | P2RX7 2059/4885L3MBTL1 2006/4885POLB 3970/4885 |
| US-20090088425-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, MC2R | P2RX7 990/4885L3MBTL1 2134/4885POLB 3277/4885 |
| US-20210040073-A1 | AZABICYCLO-SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREOF, AND APPLICATION OF SAME IN MEDICINE | OXTR, CRH, MC2R | P2RX7 1741/4885L3MBTL1 4691/4885POLB 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.